Natasha Manning
Psychiatric/Mental Health · Buffalo, NYNPI 1407146558
Payments from drug & device makers
Across 64 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$183
- GSK$163
- AstraZeneca$143
- Novo Nordisk$140
- Aurinia Pharma U.S., Inc.$114
- Lilly USA, LLC$75
- plus $614 from 21 others
What the payments were for
- Food & beverage$1,432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $183 |
| GSK | 3 | $163 |
| AstraZeneca | 4 | $143 |
| Novo Nordisk | 8 | $140 |
| Aurinia Pharma U.S., Inc. | 1 | $114 |
| Lilly USA, LLC | 4 | $75 |
| Gilead | 3 | $74 |
| Dexcom, Inc. | 4 | $54 |
| Insulet Corporation | 2 | $52 |
| Alkermes, Inc. | 2 | $40 |
| Exact Sciences | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Misonix Inc | 1 | $36 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Mylan Specialty L.p. | 1 | $26 |
| Pfizer | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| IBSA Pharma Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Mannkind Corporation | 1 | $14 |
| Almatica Pharma LLC | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$123
- LUPKYNIS$114
How this compares
$1,432 in reported general payments places this provider in the 70th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $41,289 |
| TrulicityDulaglutide | 24 | $33,744 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $22,624 |
| LinzessLinaclotide | 18 | $22,254 |
| OzempicSemaglutide | 15 | $21,370 |
| JardianceEmpagliflozin | 13 | $15,103 |
| EliquisApixaban | 15 | $10,995 |
| FarxigaDapagliflozin Propanediol | 11 | $10,824 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 245 | $5,712 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 37 | $5,631 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,907 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 156 | $3,271 |
| Atorvastatin Calcium | 173 | $1,702 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,307 |
| Omeprazole | 91 | $1,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $163 | $41,28942 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $143 | $38,35551 claims |
| Lilly USA, LLCTrulicity | $75 | $33,74424 claims |
| AbbVieLinzess | $183 | $22,25418 claims |
| Novo NordiskOzempic | $140 | $21,37015 claims |
| Boehringer IngelheimJardiance | $20 | $15,10313 claims |
| PfizerEliquis | $24 | $10,99515 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $37231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Buffalo
- Carl de FrancoBuffalo$28K
- Sarah OtwellBuffalo$15K
- Tisha TanyiBuffalo$10K
- Richard ZawislakBuffalo$10K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.